---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-342378"
form_type: "8-K"
ticker: "ALMR"
cik: "0002104204"
company_name: "Alamar Biosciences, Inc."
filed_at: "2026-08-10T20:10:17+00:00"
generated_at: "2026-08-10T20:11:28.167574+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Alamar Q2 revenue $29.4M (+82% YoY); guides FY26 to $116-120M

## Summary
- Q2 revenue $29.4M, up 82% from $16.2M YoY; consumables +147% to $15.5M, instruments +35% to $7.8M.
- Gross margin improved to 60% vs 53% YoY; operating loss widened to $13.5M from $7.9M.
- Net loss $13.2M vs $7.0M YoY; cash and investments $256.3M at June 30, 2026.
- FY2026 revenue guidance raised to $116-120M, ~59% growth at midpoint vs 2025.
- Launched eMTBR-tau blood assay and NULISAseq Immune 340 Panel; expanded Alzheimer's partnership with Gates Ventures.

## SEC filing metadata
- accession: 0001193125-26-342378
- form_type: 8-K
- ticker: ALMR
- cik: 0002104204
- company_name: Alamar Biosciences, Inc.
- filed_at: 2026-08-10T20:10:17+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2104204/000119312526342378/0001193125-26-342378-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2104204/000119312526342378/ck0002104204-20260810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-342378
- JSON: https://secwatch.observer/filing/0001193125-26-342378.json
- Plain text: https://secwatch.observer/filing/0001193125-26-342378.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.